JP2012518399A5 - - Google Patents

Download PDF

Info

Publication number
JP2012518399A5
JP2012518399A5 JP2011550602A JP2011550602A JP2012518399A5 JP 2012518399 A5 JP2012518399 A5 JP 2012518399A5 JP 2011550602 A JP2011550602 A JP 2011550602A JP 2011550602 A JP2011550602 A JP 2011550602A JP 2012518399 A5 JP2012518399 A5 JP 2012518399A5
Authority
JP
Japan
Prior art keywords
antigen
binding
cancer
binding construct
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011550602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012518399A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/052284 external-priority patent/WO2010097386A1/en
Publication of JP2012518399A publication Critical patent/JP2012518399A/ja
Publication of JP2012518399A5 publication Critical patent/JP2012518399A5/ja
Pending legal-status Critical Current

Links

JP2011550602A 2009-02-24 2010-02-23 抗原結合性構築物 Pending JP2012518399A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15489209P 2009-02-24 2009-02-24
US61/154,892 2009-02-24
PCT/EP2010/052284 WO2010097386A1 (en) 2009-02-24 2010-02-23 Antigen-binding constructs

Publications (2)

Publication Number Publication Date
JP2012518399A JP2012518399A (ja) 2012-08-16
JP2012518399A5 true JP2012518399A5 (enExample) 2013-04-11

Family

ID=42123027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011550602A Pending JP2012518399A (ja) 2009-02-24 2010-02-23 抗原結合性構築物

Country Status (5)

Country Link
US (1) US20110305693A1 (enExample)
EP (1) EP2401297A1 (enExample)
JP (1) JP2012518399A (enExample)
CA (1) CA2753332A1 (enExample)
WO (1) WO2010097386A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2763493A1 (en) * 2009-05-28 2010-12-02 Glaxo Group Ltd. Antigen-binding proteins
CN102352368B (zh) * 2011-09-29 2013-12-04 苏州大学 Ing4与osm双基因共表达载体及其应用
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
TW201829462A (zh) * 2016-11-02 2018-08-16 英商葛蘭素史克智慧財產(第二)有限公司 結合蛋白
CN110057877A (zh) * 2018-12-24 2019-07-26 中山大学 可重复修饰的用于检测肿瘤细胞的生物传感器及其制备法
US20250297020A1 (en) * 2021-11-23 2025-09-25 Adalta Limited Rank-l binding molecules

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
DK1801214T3 (da) 1997-07-07 2011-01-24 Medical Res Council In vitro sorteringsfremgangsmåde
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
ATE380865T1 (de) 1998-05-13 2007-12-15 Domantis Ltd Phagen-display-selektionssystem für korrekt gefaltete proteine
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
GB9900298D0 (en) 1999-01-07 1999-02-24 Medical Res Council Optical sorting method
JP2003523742A (ja) 2000-02-03 2003-08-12 ドマンティス リミテッド コンビナトリアルタンパク質ドメイン
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
ES2706902T3 (es) 2001-06-26 2019-04-01 Amgen Inc Anticuerpos para OPGL
CA2457636C (en) 2001-08-10 2012-01-03 Aberdeen University Antigen binding domains
CA2531238C (en) 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
KR20060129246A (ko) 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
US7476724B2 (en) 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
JP2009526857A (ja) 2006-02-15 2009-07-23 イムクローン・リミテッド・ライアビリティ・カンパニー 機能性抗体
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
CN101796072B (zh) * 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
SG191639A1 (en) * 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof

Similar Documents

Publication Publication Date Title
JP2012518398A5 (enExample)
JP2012518399A5 (enExample)
CN110627906A (zh) 抗pd-l1/4-1bb双特异性抗体及其用途
JP2019533807A5 (enExample)
JP2016524592A5 (enExample)
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
CY1118693T1 (el) Αντισωματα αντι-ακτιβινης α και χρησεις αυτων
JP2020525032A5 (enExample)
JP2019528061A5 (enExample)
JP2018527919A5 (enExample)
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
JP2017029157A5 (enExample)
RU2016101711A (ru) Высокостабильный т-клеточный рецептор и способ его получения и применения
RU2015146419A (ru) Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl
CN106749677B (zh) 一种靶向mll白血病的双特异性嵌合抗原受体基因及其应用
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
JP2018525032A5 (enExample)
RU2011143903A (ru) Антитела к человеческому tweak и их применение
JP2014515600A5 (enExample)
WO2022179580A1 (zh) 一种抗NKp30抗体及其应用
JP2020505075A5 (enExample)
CN103497253A (zh) 一种针对h2a.z变体的纳米抗体、其编码序列及应用
CN118324917A (zh) 一种靶向trop2的鲨鱼单域抗体和免疫毒素及其应用
HRP20180917T1 (hr) Novi fragmenti protutijela, pripravci i njihova upotreba
CN117820475B (zh) 针对il-17a的新型纳米抗体、药物、制备、方法及应用